Andrew J. Armstrong, MD, MSc, Duke Cancer Institute, Durham, NC, discusses The Phase III PANTHER (NCT03098836) trial of apalutamide and abiraterone acetate plus prednisone (AAAP) in Black and White men with metastatic castrate-resistant prostate cancer. This multicenter study enrolled 43 Black and 50 White patients and assessed radiographic progression-free survival (rPFS), time to PSA progression (TTP), overall survival (OS), and best PSA response as primary and secondary endpoints. Baseline characteristics were largely similar between the two groups. Interim analysis revealed events in rPFS and deaths in both Black and White patients. The study suggests that AAAP combination therapy may hold clinical efficacy for Black men with mCRPC, but further investigation is needed to understand potential benefits in this understudied population. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.